GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung ...

GSK plans to take the TCE to Phase I clinical trials in multiple myeloma during 2027.

Shares rose after strong clinical data strengthened the case for its $10.6 billion Nuvalent acquisition and broader push to rebuild oncology around lung cancer.

GSK plc GSK has entered into an agreement to acquire an investigational trispecific T-cell engager (TCE) from Chimagen ...

GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start ...

GSK has agreed to acquire full global rights to a potential best-in-class trispecific T-cell engager from Chimagen Biosciences in a transaction worth up to $750 million, expanding the pharmaceutical ...

The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms ...

GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an ...

Sept 15 (Reuters) - GSK said on Tuesday it had agreed a deal worth up to $750 million to buy a trispecific T cell-engager (TCE), a drug designed to help T-cells target cancer, from China-based ...

LONDON, June 9 (Reuters) - GSK (GSK.L), opens new tab has agreed to buy U.S.-listed cancer drug developer Nuvalent (NUVL.O), opens new tab for $10.6 billion in its largest deal in more than a decade, ...